Description

Mibenratide is a synthetically produced, small cyclic peptide that acts as a selective ??-adrenergic receptor antagonist, making it a valuable tool in cardiovascular research—particularly heart failure models. With a purity of 99.77% (HPLC, GMP-grade), it ensures reliable performance across labs. Its cyclic structure delivers enhanced stability and receptor-binding specificity. Widely utilized to probe ??-adrenergic signaling pathways, Mibenratide supports translational research into conditions such as heart failure, cardiomyopathy, and arrhythmias. Synthesized under rigorous GMP conditions, Mibenratide assures high reproducibility and documentation for both wholesale and retail lab environments.

Mibenratide Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Mibenratide is a cyclic peptide that effectively antagonizes the ??-adrenergic receptor, blocking its downstream signaling. This interaction helps modulate cardiac responses mediated by sympathetic stimulation and is instrumental in dissecting ??-AR–driven pathways in research contexts.

Research Applications

• Heart Failure Models: Analyze the impact of ??-AR blockade on cardiac contractility and remodeling.

• Cardiac Signaling Probing: Study second-messenger pathways, G-protein coupling, and receptor binding kinetics.

• Comparative Pharmacology: Use Mibenratide alongside established ?-blockers (e.g., metoprolol, bisoprolol) in head-to-head assays.

• Safety and PK Profiling: Model pharmacokinetics and receptor kinetics in vitro and in vivo studies.

Development & Formulation Notes

Mibenratide is supplied as a standard lyophilized peptide. For experimental use, dissolve in sterile water or buffer; DMSO may aid solubility. Prepare aliquots to minimize freeze–thaw cycles. It is stable long-term at –20 °C in a dry environment and in solution at –80 °C. For kinetic assays, ensure correct concentrations and maintain sample integrity throughout handling.

Disclaimer

Mibenratide is provided strictly for laboratory research use only. It is not a pharmaceutical product or medical device and is not approved for clinical, diagnostic, or veterinary applications. Users must follow institutional biosafety protocols and handle the material responsibly. All experimental outcomes are the user’s responsibility.

Packaging & Availability

• Standard Packs: 1 mg, 5 mg, 10 mg (for small-scale research)

• Bulk/Wholesale: Multi-gram lots with batch reservation and continuity
  Each lot includes a CoA documenting purity, identity, and initial QC data.

Quality Assurance

Produced under GMP guidelines, Mibenratide undergoes stringent identity and purity testing (MS, HPLC). Stability, appearance, and moisture content are provided per lot. Customized QC documentation is available for institutional audits or compliance needs.

Custom Services

• Custom Aliquoting & Labeling: For seamless integration into LIMS or ELN systems

• Formulation Support: Expert guidance on reconstitution and buffer systems

• Stability Study Planning: For tailored storage and transport conditions

• Experimental Design Assistance: Support for designing heart failure or receptor-binding assays

Keywords

Mibenratide; cyclic ??-adrenergic receptor antagonist; heart failure research peptide; cardiovascular research; GMP peptide; CAS 1239011-83-6; ??-AR blocker; research-use-only peptide; receptor signaling studies.